Header Ads


US experts: "new medicine" without vaccine against "new crown", good idea but long way forward

US experts: "new medicine" without vaccine against "new crown", good idea but long way forward


A team of scientists in China told the media a few days ago that their latest research results are expected to develop an effective drug against the new coronavirus, which can prevent the virus even without a vaccine. American medical scientists said that this research may have "potential", but if it is put into practice, the future is still long.

Since the outbreak of the new coronavirus first spread in China at the end of last year, it has spread to most countries around the world, and no effective therapeutic drugs and vaccines have been found. Scientists from all over the world show their magical powers and are working day and night to develop drugs and vaccines.

Scientists at Peking University in China revealed to the media on Tuesday (May 19) that one of their laboratories has been developing a drug, and their research results show that the drug has the ability to stop the global pandemic of new coronavirus.

Scientists involved in research and development said that a drug being tested by the team's researchers not only shortens the recovery time of infected people, but also can provide short-term immunity to the virus.

Dr. Laura H. Kahn / Princeton University of the Princeton University Science and Global Security Program told VOA that, based on her professional judgment, this research may have "potential".

The report of the research results of this team of scientists of Peking University was published in the biweekly journal of the biological sciences "Cell" on May 17. The chief scientist of this research project, Xie Xiaoliang, told AFP: "Even if there is no vaccine, we can use this effective drug to stop the new coronary disease epidemic."

No vaccine can prevent new coronavirus infection! If such a special effect drug is successfully developed, it is undoubtedly good news for the world to suffer from the plight of having neither therapeutic drugs nor preventive vaccines.

Dr. Laura Kahn of Princeton University told VOA that the drug developed by Peking University scientists is a biological agent developed using personal antibodies (antibodies from patients recovering from New Coronary Virus [COVID-19]). This process is called "passive immunity".

Dr. Kahn explained: "It is similar to lactating babies ingesting their mother's antibodies during breastfeeding, so maternal antibodies help protect the baby from infection. These antibodies from patients recovering from New Coronavirus should theoretically help Neutralize the toxicity of the virus; depending on how long this antibody stays in the body, it can help prevent this disease. "

Dr. Sheng Zongmei is a vaccine expert at the National Institute of Allergy and Infectious Diseases (Dr. Zongmei Sheng / NIAID).

Dr. Sheng Zongmei told VOA: "I will not call it a 'drug'. This is actually an antibody, just like some hospitals currently use the plasma treatment of rehabilitation new crown patients. Because the plasma of rehabilitation patients contains immunity The neutralizing antibody produced by the reaction can lead to a definite clinical improvement. "

Dr. Sheng Zongmei said that because the neutralizing antibody of the new coronavirus (SARS-COV2) can defend against this virus, "so it can be used for both treatment and prevention."

The research report of Peking University scientists said in the introduction that the research team "through high-throughput single-cell RNA and VDJ sequencing, quickly recognized SARS-CoV-2 neutralizing antibodies from antigen-enriched B cells of 60 recovered patients. The main conclusion of the report is: "Human neutralizing antibodies can be effectively discovered through high-throughput single B-cell sequencing and used to respond to global pandemic infectious diseases."

Dr. Sheng Zongmei, a vaccine expert at the American Institute of Allergy and Infectious Diseases, is cautiously optimistic about the study.

Dr. Sheng Zongmei said: "Because the plasma in the recovered patients cannot be produced on a large scale, this is why they try to use single B-cells in order to be able to produce in large quantities. This is a good idea, but it will be a rather long process. Know whether it will eventually become a reality. "

The chief scientist of the Peking University team and the director of the Peking University Genomics Advanced Innovation Center, Xie Xiaoliang (Sunney Xie / Peking University), said in an exclusive interview with Agence France-Presse that the drug had achieved success in animal testing.

Xie Xiaoliang said: "We injected neutralizing antibodies into infected mice, and the viral load of mice was reduced by 2,500 times after five days. This means that this potential drug has therapeutic effects."

Given that this study has just completed small animal clinical trials, how long does it take to become a special drug for the treatment of new coronavirus disease (COVID-19 China called "new coronary pneumonia")?

Dr. Laura H. Kahn of Princeton University said: "Before it is approved for widespread use, phase I, II, III, three different phases of clinical research must be conducted to evaluate its efficacy and safety. The clinical research phase often takes a long time. I cannot give an exact time frame. "

The title of the research report published by the Peking University team in the journal "Cell" is: "Identifying effective neutralizing antibodies against the new crown through high-throughput single-cell sequencing of rehabilitation patients' B cells."

"Cell" official website introduces the publication "an extraordinary discovery published in the field of experimental biology, including but not limited to cell biology, molecular biology, neuroscience, immunology, virology and microbiology, cancer, human genetics, Systems biology, signaling, disease mechanisms, and treatment. "

No comments